课题基金 / 基金详情

Regulation of Cannabinoid Metabolism by Hepatic FABPs

Regulation of Cannabinoid Metabolism by Hepatic FABPs
肝脏 FABP 对大麻素代谢的调节
批准号:
9333074
负责人:
Matthew William Elmes
金额:
$3.38万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-08-13 至 2018-08-12

项目摘要

项目成果

Matthew William Elmes的其他基金

相关文献

中文摘要
翻译
项目摘要 临床上越来越多的大麻类药物的使用凸显了开发出更完整的 对大麻素药代动力学的认识和预测潜在的药物-药物相互作用 与其他常用的处方药一起服用。在给药后,包括∆9在内的大麻类物质- 四氢大麻酚(THC)主要由细胞色素P450酶在体内代谢和失活。 肝脏。这些代谢酶仅位于细胞内,而大麻素则定位于细胞内。 由于其高度疏水的性质,膜。一种蛋白质介导的细胞质转运 必须存在将大麻素运送到细胞内以进行后续新陈代谢的机制。大麻素转运 在肝细胞内仍然没有得到很好的描述,突显了我们对 植物大麻素失活。促进细胞内穿梭的肝脏蛋白的鉴定 外源大麻素将极大地提高我们对大麻素失活的认识。海流 该提案将检验肝脏脂肪酸结合蛋白(FABP)介导植物大麻素的假设 通过将这些亲脂化合物运送到它们的细胞内代谢酶来进行代谢 生物转化和消除。除植物大麻素外,肝脏FABP还可结合和转运 大量临床使用的药物,因此为药物-药物相互作用提供了一个潜在的新场所。 本研究项目的主要目的是检验肝脏FABP影响THC的假设。 药代动力学,因此影响的大小和持续时间。在第一个目标中, FABP1在THC代谢中的作用将在体外进行探索,利用来自野生型和 FABP1基因敲除小鼠。第二个目标将描述大麻素新陈代谢和疗效的差异。 在野生型和FABP1基因敲除小鼠之间。代谢物的产生将通过液体进行检测 色质联用时,将通过实时监测 生理和行为方面的影响。这项工作的结果将确定FABP为新的监管机构 大麻素代谢,并可用于预测由于竞争结合而引起的药物-药物相互作用, 和随后的吸收,在联邦航空局。
英文摘要
Project Summary The increasing clinical use of cannabinoids highlights the importance of developing a more complete understanding of cannabinoid pharmacokinetics and predicting potential drug-drug interactions of cannabinoids with other commonly prescribed medications. Following administration, cannabinoids including ∆9- tetrahydrocannabinol (THC) are metabolized and inactivated by cytochrome P450 enzymes primarily within the liver. These metabolic enzymes are solely located intracellularly, yet cannabinoids localize to cellular membranes as a result of their highly hydrophobic nature. A protein-mediated cytoplasmic transport mechanism must exist to shuttle cannabinoids into the cell for subsequent metabolism. Cannabinoid transport within hepatocytes remains poorly characterized, highlighting a major gap in our knowledge of phytocannabinoid inactivation. Identification of hepatic proteins that facilitate intracellular shuttling of exogenous cannabinoids would greatly enhance our knowledge of cannabinoid inactivation. The current proposal will test the hypothesis that hepatic fatty acid binding proteins (FABPs) mediate phytocannabinoid metabolism by shuttling these lipophilic compounds to their intracellular metabolic enzymes for subsequent biotransformation and elimination. In addition to phytocannabinoids, hepatic FABPs bind to and transport numerous clinically used drugs and therefore present a potential new site of drug-drug interactions. The principal goal of this research project is to test the hypothesis that hepatic FABPs influence THC pharmacokinetics and consequently the magnitude and duration of THC effects. In the first aim, the role of FABP1 in THC metabolism will be explored in vitro, utilizing primary hepatocytes derived from wild-type and FABP1 knockout mice. The second aim will characterize differences in cannabinoid metabolism and efficacy between wild-type and FABP1 knock out mice. Metabolite production will be examined by liquid chromatography mass spectrometry while THC efficacy will be examined by real-time monitoring of physiological and behavioral THC effects. The outcome of this work will identify FABPs as novel regulators of cannabinoid metabolism and may serve to predict drug-drug interactions caused by competition for binding, and subsequent uptake, at the FABPs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Regulation of Cannabinoid Metabolism by Hepatic FABPs